2,6-Dimethoxy-4-(4-(2-morpholinopyrimidin-4-yl)thiazol-2-yl)phenol | 1194819-56-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2,6-Dimethoxy-4-(4-(2-morpholinopyrimidin-4-yl)thiazol-2-yl)phenol
• 英文别名: 2,6-dimethoxy-4-[4-(2-morpholin-4-ylpyrimidin-4-yl)-1,3-thiazol-2-yl]phenol
• CAS: 1194819-56-1
• 化学式: C₁₉H₂₀N₄O₄S
• 分子量: 400.458
• InChiKey: HACJQYMPFROOOI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  118
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  4-hydroxy-3,5-dimethoxyphenylboronic acid 、 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 生成 2,6-Dimethoxy-4-(4-(2-morpholinopyrimidin-4-yl)thiazol-2-yl)phenol
  参考文献：
  名称：

  Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR

  摘要：

  A pharmacophore mapping approach, derived from previous experience of PIKK family enzymes, was used to identify a hit series of selective inhibitors of the mammalian target of rapamycin (mTOR). Subsequent refinement of the SAR around this hit series based on a tri-substituted triazine scaffold has led to the discovery of potent and selective inhibitors of mTOR. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.08.069

文献信息

• Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR
  作者：Keith A. Menear、Sylvie Gomez、Karine Malagu、Christine Bailey、Kristel Blackburn、Xiao-Ling Cockcroft、Sally Ewen、Alexandra Fundo、Armelle Le Gall、Gesine Hermann、Luisa Sebastian、Mihiro Sunose、Thomas Presnot、Eleanor Torode、Ian Hickson、Niall M.B. Martin、Graeme C.M. Smith、Kurt G. Pike

  DOI：10.1016/j.bmcl.2009.08.069

  日期：2009.10

  A pharmacophore mapping approach, derived from previous experience of PIKK family enzymes, was used to identify a hit series of selective inhibitors of the mammalian target of rapamycin (mTOR). Subsequent refinement of the SAR around this hit series based on a tri-substituted triazine scaffold has led to the discovery of potent and selective inhibitors of mTOR. (C) 2009 Elsevier Ltd. All rights reserved.